RTHM

RTHM RTHM is a secure health platform that makes it easy to gather your records, connect the dots with AI, and affordably access treatments.

The FDA has approved ensitrelvir, sold as Xocova, as the first oral antiviral for post-exposure prevention of COVID-19 i...
06/17/2026

The FDA has approved ensitrelvir, sold as Xocova, as the first oral antiviral for post-exposure prevention of COVID-19 in people aged 12 years and older after close contact with someone who has COVID-19.

The approval was based on a phase 3 study (linked below) published in The New England Journal of Medicine, which tested a 5-day course of ensitrelvir in household contacts enrolled within 72 hours of exposure to SARS-CoV-2.

The study found that ensitrelvir significantly reduced symptomatic COVID-19 compared with placebo: 2.4% vs 9.9%. It also reduced overall SARS-CoV-2 infections, including asymptomatic infections, and showed evidence of suppressing viral replication.

Side effects were similar between groups, and serious adverse events were uncommon.
Ensitrelvir is already approved in Japan for treating mild-to-moderate COVID-19, but in the U.S., it is only FDA-approved for post-exposure prevention, not acute COVID-19 treatment.

Read the full study: https://doi.org/10.1056/NEJMoa2509306

The Long COVID Treatment Guide webinar starts in 1 hour!Join Dr. Zachary Spiritos, Dr. Binita Kane, Patient-Led Research...
06/12/2026

The Long COVID Treatment Guide webinar starts in 1 hour!

Join Dr. Zachary Spiritos, Dr. Binita Kane, Patient-Led Research Collaborative (PLRC), and RTHM for a live discussion on the new Long COVID Treatment Guide.

Time: 9:30 a.m. PST / / 12:30 p.m. EST / / 5:30 p.m. GMT+1

Our panelists will discuss why this guide was created and how to best use it to explore treatment options available today while clinical trials are ongoing.

Register at the link in bio.
🔗: https://t.co/2StFgiyF4X

This week, here are five recent publications related to Long COVID, including studies on cardiovascular risk, noradrener...
06/11/2026

This week, here are five recent publications related to Long COVID, including studies on cardiovascular risk, noradrenergic dysfunction, and herpesvirus reactivation, as well as the real-world impact of Long COVID in children.

Sign up for RTHM to receive studies curated to your health conditions, symptoms, and topics of interest.

Don’t have Long COVID? You can select the conditions, symptoms, and topics that are relevant to you and receive a curated research email about those items weekly.

Sign up for weekly curated research emails here: https://www.rthm.com/research-corner/tags
You can find a clickable link in our bio.

Tomorrow, join Dr. Zachary Spiritos, Dr. Binita Kane, Patient-Led Research Collaborative (), and RTHM for a live discuss...
06/11/2026

Tomorrow, join Dr. Zachary Spiritos, Dr. Binita Kane, Patient-Led Research Collaborative (), and RTHM for a live discussion on the new Long COVID Treatment Guide.

Date: Friday, June 12
Time: 9:30 a.m. PST / / 12:30 p.m. EST / / 5:30 p.m. GMT+1

Our panelists will discuss why this guide was created and how to best use it to explore treatment options available today while clinical trials are ongoing.

🔗: https://us06web.zoom.us/j/87389631567?pwd=1hcswwamjuCTUXeEkfJTlX4Tb5dDPe.1

06/09/2026

A practical tool for the real world: concise, actionable, and built for a short primary care visit – that’s the Long COVID Treatment Guide from Patient-Led Research Collaborative (PLRC) and RTHM. It helps patients and their clinicians focus on the most actionable next steps without overwhelm.

Listen as Charlie McCone and Dr. Jennifer Curtin discuss on POTScast Ep. 306 how this focused, evidence-grounded guide can make a difference in care as more Long COVID clinics continue to close.

Want to learn more about the Long COVID Treatment Guide? Join Dr. Zachary Spiritos, Dr. Binita Kane, PLRC, and RTHM this Friday for a live webinar on the new Long COVID Treatment Guide.

Register at the link in bio.

🔗: https://us06web.zoom.us/j/87389631567?pwd=1hcswwamjuCTUXeEkfJTlX4Tb5dDPe.1

Next Friday, join Dr. Zachary Spiritos, Dr. Binita Kane, Patient-Led Research Collaborative (PLRC), and RTHM for a live ...
06/04/2026

Next Friday, join Dr. Zachary Spiritos, Dr. Binita Kane, Patient-Led Research Collaborative (PLRC), and RTHM for a live discussion on the new Long COVID Treatment Guide.

Date: Friday, June 12
Time: 9:30 a.m. PST / / 12:30 p.m. EST / / 5:30 p.m. GMT+1

The Long COVID Treatment Guide was created by PLRC and RTHM to spark meaningful conversations between patients and clinicians about treatment options that can be considered as part of a personalized care plan. It includes 24 prescription medications, along with a limited number of supplements, over-the-counter medications, procedures, and lifestyle strategies.

Our panelists will discuss why this guide was created and how to best use it to explore treatment options available today while clinical trials are ongoing.

🔗: https://us06web.zoom.us/j/87389631567?pwd=1hcswwamjuCTUXeEkfJTlX4Tb5dDPe.1

Patient-Led Research Collaborative (PLRC) and RTHM Clinic recently released the Long COVID Treatment Guide to support mo...
06/02/2026

Patient-Led Research Collaborative (PLRC) and RTHM Clinic recently released the Long COVID Treatment Guide to support more informed conversations between patients and their clinicians.

The guide covers over 30 different interventions. Today, we’re highlighting intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), immunoglobulin therapies that may be especially relevant for people with Long COVID who have developed certain types of neuropathy, ME/CFS, immune deficiency, autoimmune disease, autonomic dysfunction, or who have not responded to other therapies.

Across reviewed data, IVIG demonstrated therapeutic potential for infection-associated and immune-mediated conditions. Five papers on post-COVID small fiber neuropathy reported 60–100% response rates, and two studies on autoimmune dysautonomia reported 40–80% functional improvement. In ME/CFS, three studies reported positive outcomes, and several mechanistic or review papers supported IVIG’s immunomodulatory rationale.
In the Harvard/Stanford/OMF TREATME study, 42% of individuals with Long COVID or ME/CFS who tried IVIG/SCIG reported moderate to much better symptom improvement. The NIH RECOVER IVIG study is also underway to further evaluate efficacy in Long COVID.

As with all treatments in the guide, IVIG/SCIG should be discussed with a qualified clinician to determine whether it is appropriate for an individual case, including review of risks, contraindications, drug interactions, allergies, and potential side effects. The treatment guide is an evidence-grounded resource designed to support patients and clinicians in making informed decisions together.

Download the guide here: https://www.rthm.com/treatmentguide

Join RTHM, Patient-Led Research Collaborative (PLRC), Dr. Zachary Spiritos, and Dr. Binita Kane on June 12 at 9:30 a.m. ...
05/29/2026

Join RTHM, Patient-Led Research Collaborative (PLRC), Dr. Zachary Spiritos, and Dr. Binita Kane on June 12 at 9:30 a.m. PST // 12:30 p.m. EST // 5:30 p.m. GMT+1 for a live discussion on the new Long COVID Treatment Guide.

The Long COVID Treatment Guide was created by PLRC and RTHM to spark meaningful conversations between patients and clinicians about treatment options that can be considered as part of a personalized care plan. It includes 24 prescription medications, along with a limited number of supplements, over-the-counter medications, procedures, and lifestyle strategies.

Our panelists will discuss why this guide was created and how to best use it to explore treatment options available today while clinical trials are ongoing.

Panelists include:
Binita Kane, MD
Zachary Spiritos, MD, MPH
Charlie McCone
Jennifer Curtin, MD

Register here: https://us06web.zoom.us/j/87389631567?pwd=1hcswwamjuCTUXeEkfJTlX4Tb5dDPe.1

Want to know how the latest Long COVID research relates to your case?Sign up for RTHM to receive studies curated to your...
05/27/2026

Want to know how the latest Long COVID research relates to your case?

Sign up for RTHM to receive studies curated to your health conditions, symptoms, and topics of interest.

This week, here are five recent publications related to Long COVID, ranging from immune and vascular changes to viral reactivation.

Don’t have Long COVID? You can select conditions, symptoms and topics that are relevant to you and receive a curated research email about those items weekly.

Sign up for weekly curated research emails here: https://www.rthm.com/research-corner/tags

Have you tried ketotifen for Long COVID, ME/CFS, or MCAS-related symptoms?According to our data from patients prescribed...
05/22/2026

Have you tried ketotifen for Long COVID, ME/CFS, or MCAS-related symptoms?

According to our data from patients prescribed ketotifen through RTHM, 41% reported improvements in their symptoms, and 32% of those who improved experienced significant benefits.

Ketotifen works as an oral antihistamine and mast cell stabilizer, helping calm overactive immune responses that may contribute to allergic symptoms, food intolerances, poor sleep, GI symptoms, and post-exertional malaise (PEM).

Swipe to see why some RTHM users are finding ketotifen to be a helpful tool in managing complex chronic illness.

You can explore whether compounded oral ketotifen is right for you through a clinician-reviewed treatment assessment. Click the link in our bio to get started.

Address

2261 Market Street #10535
San Francisco, CA
94114

Website

,

Alerts

Be the first to know and let us send you an email when RTHM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category